KR900007435A - 인슐린 유도체, 이의 용도, 및 이를 함유하는 약제학적 조성물 - Google Patents

인슐린 유도체, 이의 용도, 및 이를 함유하는 약제학적 조성물 Download PDF

Info

Publication number
KR900007435A
KR900007435A KR1019890016137A KR890016137A KR900007435A KR 900007435 A KR900007435 A KR 900007435A KR 1019890016137 A KR1019890016137 A KR 1019890016137A KR 890016137 A KR890016137 A KR 890016137A KR 900007435 A KR900007435 A KR 900007435A
Authority
KR
South Korea
Prior art keywords
physiologically acceptable
insulin
amino acid
formula
general
Prior art date
Application number
KR1019890016137A
Other languages
English (en)
Other versions
KR0158197B1 (ko
Inventor
되르슈 미챌
Original Assignee
베른 하르트 베크, 하인리히 벡커
훽스트 아크티엔 게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6366698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR900007435(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 베른 하르트 베크, 하인리히 벡커, 훽스트 아크티엔 게젤샤프트 filed Critical 베른 하르트 베크, 하인리히 벡커
Publication of KR900007435A publication Critical patent/KR900007435A/ko
Application granted granted Critical
Publication of KR0158197B1 publication Critical patent/KR0158197B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

내용 없음

Description

인슐린 유도체, 이의 용도, 및 이를 함유하는 약제학적 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 5내지 8.5의 등전점을 갖는 일반식(Ⅱ)의 인슐린 유도체 및 이의 생리학적으로 허용되는 염.
    상기식에서, R1은 H 또는 H-Phe이고, R2는 아미드 그룹을 함유하지 않은 유전적으로 암호화될 수 있는 L-아미노산이며, R30은 유전적으로 암호화될수 있는 중성 L-아미노산이고, R31은 본질적으로 염기성이며 50개 이하의 탄소원자를 갖는 생리학적으로 허용되는 유기그룹이고, 이의 구조에는 0내지 3개의 α-아미노산이 포함되고 이의 말단 카복실 그룹은, 경우에 따라 유리된 상태로 존재할 수 있거나, 에스테르 작용기, 아미드 작용기, 락톤 또는 환원된 CH2OH 형태로 존재하며, X는 유전적으로 암호화될 수 있는 L-아미노산이다.
  2. 제1항에 있어서, 일반적(Ⅱ)의 , R1이 H-Phe인 인슐린 유도체 및 이의 생리학적으로 허용되는 염.
  3. 제1항 또는 2항에 있어서, 일반적(Ⅱ)의 , R2가 Gly, Ala, Ser, Thr, Asp 또는 Glu, 특히 Asp인 인슐린 유도체 및 이의 생리학적으로 허용되는 염.
  4. 제1항 내지 3항중 어느 한 항에 있어서, 일반적(Ⅱ)의 R30이 Ala, Thr, 또는 Ser인 인슐린 유도체 및 이의 생리학적으로 허용되는 염
  5. 제1항 내지 4항중 어느 한 항에 있어서, 일반적(Ⅱ)의 R31가 Arg-OH 또는 Arg-Arg-OH인 인슐린 유도체 및 이의 생리학적으로 허용되는 염.
  6. 제1항 내지 5항중 어느 한 항에 있어서, 일반식(Ⅲ)의 X가 Asn 또는 Gln인 인슐린 유도체 및 이의 생리학적으로 허용되는 염.
  7. 제1항 내지 6항중 어느 한 항에 있어서, 일반식(Ⅱ)의 서열(A1 내지 A20) 및 (B1 내지 B9, B11 내지 B29)가 사람, 돼지 또는 송아지 인슐린의 서열, 특히 사람 인슐린의 서열인 인슐린 유도체 및 이의 생리학적으로 허용되는 염.
  8. 당뇨병 치료를 위한 약제학적 조성물의 활성물질로서의 제1항 내지 7항중 어느 한 항에서 청구된 인슐린 유도체 및 이의 생리학적으로 허용되는 염의 용도.
  9. 용해된, 무정형 및/또는 결정성 형태, 바람직하게는 용해된 형태의 제1항 내지 7항중 어느 한 항에서 청구된 유효량의 적어도 하나의 일반식(Ⅱ)의 인슐린 유도체 및/또는 적어도 하나의 이의 생리학적으로 허용되는 염을 함유하는 약제학적 조성물.
  10. 제9항에 있어서, 4ug 내지 2mg, 바람직하게는 5ug 내지 200mg의 아연/mg을 추가로 함유하는 약제학적 조성물.
  11. 제9항 또는 10항에 있어서, 변형되지 않은 인슐린, 바람직하게는 변형되지 않은 인간 인슐린을 추가로 함유하는 약제학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890016137A 1988-11-08 1989-11-08 인슐린 유도체 및 이를 함유하는 약제학적 조성물 KR0158197B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE3837825A DE3837825A1 (de) 1988-11-08 1988-11-08 Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DEP3937825.6 1988-11-08
DEP3837825.6 1988-11-08

Publications (2)

Publication Number Publication Date
KR900007435A true KR900007435A (ko) 1990-06-01
KR0158197B1 KR0158197B1 (ko) 1998-12-01

Family

ID=6366698

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890016137A KR0158197B1 (ko) 1988-11-08 1989-11-08 인슐린 유도체 및 이를 함유하는 약제학적 조성물

Country Status (22)

Country Link
US (2) US5656722A (ko)
EP (1) EP0368187B1 (ko)
JP (1) JP2680145B2 (ko)
KR (1) KR0158197B1 (ko)
AT (1) ATE93868T1 (ko)
AU (1) AU621680B2 (ko)
CA (1) CA1339044C (ko)
DE (3) DE3837825A1 (ko)
DK (1) DK173196B1 (ko)
ES (1) ES2059676T4 (ko)
FI (1) FI100185B (ko)
HK (1) HK1006171A1 (ko)
HU (2) HU213018B (ko)
IE (1) IE63338B1 (ko)
IL (1) IL92222A (ko)
LU (1) LU90614I2 (ko)
NL (1) NL300019I2 (ko)
NO (2) NO177963C (ko)
NZ (1) NZ231272A (ko)
PH (1) PH30695A (ko)
PT (1) PT92220B (ko)
ZA (1) ZA898456B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100547922B1 (ko) * 1996-07-26 2006-06-22 훽스트 악티엔게젤샤프트 아연결합이증가된인슐린유도체및이를함유하는약제학적제제

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0547544B1 (de) * 1991-12-18 1997-03-12 Hoechst Aktiengesellschaft Verfahren zur Gewinnung von insulinhaltigen Lösungen
ATE203998T1 (de) * 1993-04-27 2001-08-15 Hoechst Ag Amorphe monosphärische formen von insulinderivaten
DE19512484A1 (de) 1995-04-04 1996-10-17 Bayer Ag Kohlenhydratmodifizierte Cytostatika
DE19652713C2 (de) * 1996-12-18 2001-11-22 Aventis Pharma Gmbh Verfahren zur Reinigung von Insulin und Insulinderivaten durch Chromatographie an stark saurem Kationenaustauscher
CA2306877A1 (en) * 1997-10-24 1999-05-06 Eli Lilly And Company Insoluble insulin compositions
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
DE19825447A1 (de) 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
DE19838097A1 (de) 1998-08-24 2000-03-02 Hoechst Marion Roussel De Gmbh Verfahren zur chromatographischen Reinigung von Insulinen
US6933272B1 (en) 1998-09-22 2005-08-23 Erik Helmerhorst Use of non-peptidyl compounds for the treatment of insulin related ailments
WO2001072323A2 (en) * 2000-03-24 2001-10-04 Genentech, Inc. Use of insulin for the treatment of cartilagenous disorders
US7316999B2 (en) 2000-06-02 2008-01-08 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
FR2822834B1 (fr) * 2001-04-02 2005-02-25 Flamel Tech Sa Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation
WO2003020201A2 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
EP2243776A1 (en) 2001-10-12 2010-10-27 High Point Pharmaceuticals, LLC Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor
US7179788B2 (en) * 2001-10-19 2007-02-20 Eli Lilly And Company Biphasic mixtures of GLP-1 and insulin
CZ2004710A3 (cs) * 2001-12-20 2005-02-16 Eli Lilly And Company Inzulínová sloučenina s protrahovaným účinkem
US7774816B2 (en) * 2002-04-23 2010-08-10 Rovi Technologies Corporation Conflict manager for a video recorder
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
FR2843117B1 (fr) * 2002-07-30 2004-10-15 Flamel Tech Sa Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
EP1615698B1 (en) 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC New amide derivatives and pharmaceutical use thereof
BRPI0409600A (pt) * 2003-04-29 2006-04-18 Lilly Co Eli análogo de insulina, composição, método de tratamento de hiperglicemia, e, análogo de pró-insulina
FR2860516B1 (fr) * 2003-10-03 2006-01-13 Flamel Tech Sa Homopolyaminoacides telecheliques fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
CN104826116A (zh) 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
FR2862536B1 (fr) * 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
FR2873040B1 (fr) 2004-07-19 2007-11-30 Flamel Technologies Sa Formulation colloidale d'insuline longue action et sa preparation
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
CN103110635A (zh) 2005-07-04 2013-05-22 海波因特制药有限责任公司 组胺h3受体拮抗剂
WO2007015805A1 (en) 2005-07-20 2007-02-08 Eli Lilly And Company 1-amino linked compounds
JP5198280B2 (ja) 2005-11-17 2013-05-15 イーライ リリー アンド カンパニー グルカゴン受容体アンタゴニスト、並びにその調製及び治療への使用
FR2896164B1 (fr) * 2006-01-18 2008-07-04 Flamel Technologies Sa Formulation colloidale d'insuline longue action et sa preparation
EP2241327A1 (en) 2006-03-15 2010-10-20 Novo Nordisk A/S Mixtures of Amylin and Insulin
JP2009531376A (ja) 2006-03-28 2009-09-03 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー ヒスタミンｈ３受容体活性を有するベンゾチアゾール
EA016415B1 (ru) 2006-04-24 2012-04-30 Эли Лилли Энд Компани Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
NZ571972A (en) 2006-05-29 2011-09-30 High Point Pharmaceuticals Llc 3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
DE102006031962A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
DE102006031955A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
US7417517B2 (en) * 2006-07-13 2008-08-26 Motorola, Inc. Method and apparatus for a communications filter
JP2011504871A (ja) 2007-06-01 2011-02-17 ノボ・ノルデイスク・エー／エス 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト
EP2164458A1 (en) 2007-06-01 2010-03-24 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
ES2558930T3 (es) 2007-08-13 2016-02-09 Novo Nordisk A/S Análogos de la insulina de acción rápida
JP5241849B2 (ja) 2007-11-16 2013-07-17 ノボ・ノルデイスク・エー／エス インスリン及びインスリン分泌性ペプチドを含む薬学的組成物
RU2524423C2 (ru) 2008-01-09 2014-07-27 Санофи-Авентис Дойчланд Гмбх Новые производные инсулина с чрезвычайно замедленным профилем время/действие
NZ586589A (en) 2008-01-09 2012-04-27 Sanofi Aventis Deutschland Novel insulin analogues having an extremely delayed time-action profile
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008025008A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008025007A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
PL219335B1 (pl) * 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
DE102009038210A1 (de) 2009-08-20 2011-03-03 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
DE102008053048A1 (de) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
DE102008051834A1 (de) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
ES2650621T3 (es) 2008-10-17 2018-01-19 Sanofi-Aventis Deutschland Gmbh Combinación de una insulina y un agonista de GLP-1
KR20110088575A (ko) 2008-11-21 2011-08-03 하이 포인트 파마슈티칼스, 엘엘씨 아다만틸 벤즈아미드 화합물
CN107080836A (zh) 2009-07-06 2017-08-22 赛诺菲-安万特德国有限公司 含有甲硫氨酸的水性胰岛素制备物
JP2012532177A (ja) * 2009-07-06 2012-12-13 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 熱及び振動安定性インスリン製剤
WO2011003823A1 (de) 2009-07-06 2011-01-13 Sanofi-Aventis Deutschland Gmbh Langsamwirkende insulinzubereitungen
MX2012001399A (es) 2009-07-31 2012-03-21 Sanofi Aventis Deutschland Profarmacos que comprenden un conjugado de insulina-conector.
SG178195A1 (en) 2009-07-31 2012-03-29 Sanofi Aventis Deutschland Long acting insulin composition
PE20121362A1 (es) 2009-11-13 2012-10-17 Sanofi Aventis Deutschland Composicion farmaceutica que comprende despro36exendina-4(1-39)-lys6-nh2, insulina gly(a21)-arg(b31)-arg(b32) y metionina
TWI468171B (zh) 2009-11-13 2015-01-11 Sanofi Aventis Deutschland 含ｇｌｐ－１激動劑及甲硫胺酸之醫藥組成物
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
RU2546520C2 (ru) 2010-08-30 2015-04-10 Санофи-Авентис Дойчланд Гмбх Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
AU2012208349A1 (en) 2011-01-20 2013-07-18 Zealand Pharma A/S Combination of acylated glucagon analogues with insulin analogues
EP2670368A4 (en) 2011-02-03 2015-04-15 Pharmedica Ltd NEW ORAL DISSOLUTION FILMS FOR INSULIN DELIVERY FOR THE TREATMENT OF DIABETES
CN102219851B (zh) 2011-05-09 2012-05-30 甘李药业有限公司 甘精胰岛素结晶的制备方法
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CA2843586A1 (fr) 2011-08-10 2013-02-14 Adocia Solution injectable d'au moins une insuline basale
CN103917241A (zh) 2011-08-29 2014-07-09 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
EP2771296B1 (en) 2011-10-25 2017-09-27 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US10350139B2 (en) 2011-10-25 2019-07-16 Corning Incorporated Pharmaceutical glass packaging assuring pharmaceutical sterility
CN104114155B (zh) 2012-01-09 2019-02-15 阿道恰公司 Ph为7并且至少包含pi为5.8至8.5之基础胰岛素和经取代共聚(氨基酸)的可注射溶液
PL222975B1 (pl) 2012-05-23 2016-09-30 Inst Biotechnologii I Antybiotyków Analog insuliny lub jego farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna o przedłużonym działaniu terapeutycznym oraz zastosowanie analogu insuliny
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
DK2854841T3 (en) 2012-06-04 2017-05-22 Diamedica Inc Kallikrein-1-glycosylation isoforms of human tissue
FR3001896B1 (fr) 2013-02-12 2015-07-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
FR3001895B1 (fr) 2013-02-12 2015-07-03 Adocia Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
US9707275B2 (en) * 2012-12-19 2017-07-18 Wockhardt Limited Stable aqueous composition comprising human insulin or an analogue or derivative thereof
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
HUE042381T2 (hu) 2013-04-03 2019-06-28 Sanofi Sa Cukorbetegség kezelése hosszan ható inzulinkészítményekkel
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707155B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9839579B2 (en) 2013-04-24 2017-12-12 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9713572B2 (en) 2013-04-24 2017-07-25 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707153B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717649B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717648B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
RU2016132342A (ru) 2014-01-09 2018-02-14 Санофи Стабилизированные фармацевтические составы на основе инсулиновых аналогов и/или инсулиновых производных
SG11201604706TA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized pharmaceutical formulations of insulin aspart
MX2016008978A (es) 2014-01-09 2016-10-04 Sanofi Sa Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
RS64300B1 (sr) 2014-12-12 2023-07-31 Sanofi Aventis Deutschland Formulacija fiksnog odnosa insulin glargina/liksisenatida
CN104688677B (zh) * 2015-02-05 2018-02-09 通化东宝药业股份有限公司 一种稳定的甘精胰岛素注射液及其制备方法
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AR107560A1 (es) 2016-02-24 2018-05-09 Lilly Co Eli Compuesto que disminuye la glucosa en la sangre
FR3052072A1 (fr) 2016-06-07 2017-12-08 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
BR112019011394A2 (pt) 2016-12-05 2019-12-10 Nuritas Ltd composições compreendendo peptídeo wkdeagkplvk
EP3329930A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Pharmaceuctical compositions
CN110446501A (zh) 2017-03-09 2019-11-12 代阿麦迪卡股份有限公司 组织激肽释放酶1的剂型
FR3070264A1 (fr) 2017-08-24 2019-03-01 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris de 5,8 a 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
EP3720472A1 (fr) 2017-12-06 2020-10-14 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3083089A1 (fr) 2018-06-29 2020-01-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
FR3083088B1 (fr) 2018-06-29 2020-10-02 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
JP2021505607A (ja) 2017-12-07 2021-02-18 アドシア ５．８〜８．５のｐＩを有する少なくとも１つの基礎インスリンならびにカルボキシレート電荷および疎水性ラジカルを有するコポリアミノ酸を含むｐＨ７の注射溶液
WO2019110773A1 (fr) 2017-12-07 2019-06-13 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
CN111836616B (zh) 2017-12-07 2024-01-16 阿道恰公司 包含至少一种pi在5.8与8.5之间的基础胰岛素和带有羧酸根电荷及疏水基的共聚氨基酸的ph 7为7的可注射溶液
KR20210005630A (ko) * 2018-04-16 2021-01-14 유니버시티 오브 유타 리서치 파운데이션 글루코스-반응성 인슐린
WO2019243628A1 (fr) 2018-06-22 2019-12-26 Adocia Composition injectable a ph 7 comprenant un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes et au moins une insuline basale presentant au moins un effet prandial et un effet basal
FR3084585B1 (fr) 2018-08-03 2020-11-06 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un compose amphiphile porteur de radicaux hydrophobes
KR20200017078A (ko) 2018-08-08 2020-02-18 주식회사 대웅제약 지속형 인슐린 아날로그 및 그 복합체
WO2020115334A1 (fr) 2018-12-07 2020-06-11 Adocia Procede de preparation d'une composition stable sous forme d'une solution aqueuse injectable
US20200179489A1 (en) 2018-12-07 2020-06-11 Adocia Injectable solution at ph 7 comprising at least one basal insulin which pi is from 5.8 to 8.5 and a co-polyamino-acid bearing carboxylate charges and hydrophobic radicals and a limited amount of m-cresol
KR20200080748A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법
KR20200080747A (ko) 2018-12-27 2020-07-07 주식회사 폴루스 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
KR20200082618A (ko) 2018-12-31 2020-07-08 주식회사 폴루스 인슐린 과발현용 램프 태그 및 이를 이용한 인슐린의 제조방법
WO2020245470A1 (fr) 2019-06-07 2020-12-10 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5, du liraglutide et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
TW202120536A (zh) 2019-07-31 2021-06-01 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
CN113105536B (zh) 2020-09-11 2023-07-18 美药星（南京）制药有限公司 一种新甘精胰岛素原及其制备甘精胰岛素的方法
CN114805610B (zh) * 2022-06-23 2022-10-04 北京惠之衡生物科技有限公司 一种高表达甘精胰岛素前体的重组基因工程菌及其构建方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3033127A1 (de) * 1980-09-03 1982-04-08 Hoechst Ag, 6000 Frankfurt Neue analoga des insulins
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
DK113585D0 (da) * 1985-03-12 1985-03-12 Novo Industri As Nye peptider
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
PH25772A (en) * 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
AU612141B2 (en) * 1987-02-25 1991-07-04 Novo Nordisk A/S Novel insulin derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100547922B1 (ko) * 1996-07-26 2006-06-22 훽스트 악티엔게젤샤프트 아연결합이증가된인슐린유도체및이를함유하는약제학적제제

Also Published As

Publication number Publication date
AU4441289A (en) 1990-05-17
NO894424D0 (no) 1989-11-07
US6100376A (en) 2000-08-08
NO177963C (no) 1995-12-27
HK1006171A1 (en) 1999-02-12
DE3837825A1 (de) 1990-05-10
HUT52549A (en) 1990-07-28
DK554789A (da) 1990-05-09
LU90614I2 (fr) 2000-09-26
IE893576L (en) 1990-05-08
DE58905456D1 (de) 1993-10-07
NL300019I1 (nl) 2000-12-01
FI895259A0 (fi) 1989-11-06
ES2059676T3 (es) 1994-11-16
HU210800A9 (en) 1995-07-28
PT92220B (pt) 1995-07-06
US5656722A (en) 1997-08-12
JP2680145B2 (ja) 1997-11-19
EP0368187A3 (de) 1991-07-03
FI100185B (fi) 1997-10-15
CA1339044C (en) 1997-04-01
NO894424L (no) 1990-05-09
NL300019I2 (nl) 2001-02-01
JPH02218696A (ja) 1990-08-31
AU621680B2 (en) 1992-03-19
ZA898456B (en) 1990-06-27
KR0158197B1 (ko) 1998-12-01
HU213018B (en) 1997-01-28
HU895678D0 (en) 1990-01-28
PT92220A (pt) 1990-05-31
NO2001023I1 (no) 2001-12-17
DE10075022I1 (de) 2000-10-05
DE10075022I2 (de) 2002-07-04
DK554789D0 (da) 1989-11-07
NO177963B (no) 1995-09-18
IL92222A0 (en) 1990-07-26
IE63338B1 (en) 1995-04-19
ES2059676T4 (es) 2012-03-13
IL92222A (en) 1999-09-22
ATE93868T1 (de) 1993-09-15
DK173196B1 (da) 2000-03-13
NZ231272A (en) 1992-11-25
PH30695A (en) 1997-09-16
EP0368187B1 (de) 1993-09-01
EP0368187A2 (de) 1990-05-16

Similar Documents

Publication Publication Date Title
KR900007435A (ko) 인슐린 유도체, 이의 용도, 및 이를 함유하는 약제학적 조성물
PH27425A (en) Insulin derivatives the use thereof and a pharmaceutical formulation containing them
KR900002801A (ko) 당뇨병 치료용 약학적제제
KR900003205A (ko) 제약 화합물
GR3020095T3 (en) Novel insulin derivatives, their preparation and use, and a pharmaceutical composition thereof

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120727

Year of fee payment: 15

FPAY Annual fee payment

Payment date: 20130723

Year of fee payment: 16

FPAY Annual fee payment

Payment date: 20140721

Year of fee payment: 17

FPAY Annual fee payment

Payment date: 20150626

Year of fee payment: 18

EXPY Expiration of term